Compounds > quinuclidines
Page last updated: 2024-08-18

quinuclidines and paclitaxel

quinuclidines has been researched along with paclitaxel in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's7 (87.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Trissel, LA; Xu, QA1
Agustoni, F; Celio, L; Damian, S; De Benedictis, E; De Braud, F; Mariani, P; Ricchini, F1
Furukawa, N; Ito, F; Kanayama, S; Tanase, Y1
Fujiwara, S; Kanemura, M; Ohmichi, M; Sasaki, H; Terai, Y; Tsunetoh, S1
Hayakawa, O; Iwasaki, M; Matsuura, M; Mizunuma, M; Nishikawa, A; Saito, T; Satohisa, S; Tanaka, R; Tanaka, S; Teramoto, M1
Furukawa, N; Ito, F1
Ishiguro, T; Ogishima, D; Ota, T; Sugimori, Y; Ujihira, T1
Cartagena-Albertus, JC; Engel Manchado, J; Moise, A; Montoya Alonso, JA; Moya García, S1

Trials

6 trial(s) available for quinuclidines and paclitaxel

ArticleYear
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
    Oncology, 2013, Volume: 84, Issue:6

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Constipation; Dexamethasone; Doxorubicin; Female; Headache; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting; Young Adult

2013
Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Constipation; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Sleep Initiation and Maintenance Disorders; Vomiting

2015
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
    Journal of gynecologic oncology, 2015, Volume: 26, Issue:4

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Cross-Over Studies; Diet; Drug Administration Schedule; Female; Genital Neoplasms, Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting

2015
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.
    The journal of obstetrics and gynaecology research, 2015, Volume: 41, Issue:10

    Topics: Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting

2015
A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
    The journal of obstetrics and gynaecology research, 2017, Volume: 43, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Outcome Assessment, Health Care; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting

2017
Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
    American journal of veterinary research, 2019, Volume: 80, Issue:6

    Topics: Animals; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Diarrhea; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Loperamide; Male; Neoplasms; Paclitaxel; Quinuclidines; Random Allocation; Vomiting

2019

Other Studies

2 other study(ies) available for quinuclidines and paclitaxel

ArticleYear
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Aug-01, Volume: 61, Issue:15

    Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Drug Combinations; Drug Stability; Injections, Intravenous; Isoquinolines; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Taxoids

2004
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:6

    Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Morpholines; Nausea; Paclitaxel; Palonosetron; Prospective Studies; Quinuclidines; Vomiting; Young Adult

2017